146141-10-8

Basic information

• Product Name: Propanamide, N-[2-(3-fluoro-2-pyridinyl)phenyl]-2,2-dimethyl-
• CAS NO: 146141-10-8
• Molecular Formula: C16H17FN2O
• Molecular Weight: 272.322
• Mol File: 146141-10-8.mol

Chemical Properties

• CAS DataBase Reference: Propanamide, N-[2-(3-fluoro-2-pyridinyl)phenyl]-2,2-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanamide, N-[2-(3-fluoro-2-pyridinyl)phenyl]-2,2-dimethyl-(146141-10-8)
• EPA Substance Registry System: Propanamide, N-[2-(3-fluoro-2-pyridinyl)phenyl]-2,2-dimethyl-(146141-10-8)

Safety Data

• Hazardous Substances Data: 146141-10-8(Hazardous Substances Data)

Upstream product

• 146141-04-0 3-fluoro-2-iodopyridine 
• 146140-95-6 2-pivaloylaminophenyl boronic acid 
• 22282-75-3 3-fluoro-4-iodopyridine 
• 17282-04-1 2-chloro-3-fluoropyridine 
• 1073354-10-5 2,2-dimethyl-N-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propionamide 
• 40273-45-8 2-bromo-3-fluoropyridine 
• 372-47-4 3-Fluoropyridine 

Downstream Products

• 153035-11-1 2,2-Dimethyl-N-(2-(3-fluoro-4-methyl-2-pyridyl)phenyl)propanamide 
• 1052686-58-4 4-bromo-2-(3-fluoropyridin-2-yl)-6-nitrophenylamine 
• 1052686-59-5 2-(3-fluoropyridin-2-yl)-6-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
• 1615683-31-2 C₂₀H₁₉FN₆O₃ 
• 1615683-35-6 C₁₆H₁₁FN₄O₃ 
• 797047-21-3 N-[4-bromo-2-(3-fluoropyridin-2-yl)phenyl]-2,2-dimethylpropionamide 
• 197177-70-1 2,2-dimethyl-N-{2-[3-fluoro-4-(2-pivaloylaminophenyl)-2-pyridyl]phenyl}propanamide 
• 197177-73-4 2,2-dimethyl-N-{2-[3-fluoro-4-(2-quinolyl)-2-pyridyl]phenyl}propanamide 
• 197177-71-2 2,2-dimethyl-N-{2-[3-fluoro-4-(2-pyridyl)-2-pyridyl]phenyl}propanamide 
• 197177-69-8 2,2-dimethyl-N-[2-(3-fluoro-4-phenyl-2-pyridyl)phenyl]propanamide 
• 197177-72-3 2,2-dimethyl-N-{2-[3-fluoro-4-(2-thienyl)-2-pyridyl]phenyl}propanamide 
• 197177-80-3 2-(3-Fluoro-4-quinolin-2-yl-pyridin-2-yl)-phenylamine 
• 197177-77-8 C₁₇H₁₄FN₃ 
• 197177-79-0 2-(3-Fluoro-4-thiophen-2-yl-pyridin-2-yl)-phenylamine 

Relevant articles and documents

Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy

A series of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV were identified and optimized to mid-to-low nanomolar potency against a variety of bacteria. However, in spite of seemingly adequate exposure achieved upon IV administration,

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships

The discovery of new antibacterial agents with novel mechanisms of action is necessary to overcome the problem of bacterial resistance that affects all currently used classes of antibiotics. Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically validated targets of the fluoroquinolone antibiotics which exert their antibacterial activity through inhibition of the catalytic subunits. Inhibition of these targets through interaction with their ATP sites has been less clinically successful. The discovery and characterization of a new class of low molecular weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presented. The benzimidazole ureas are dual targeting inhibitors of both enzymes and possess potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.

BENZIMIDAZOLE DERIVATIVES AS GYRASE INHIBITORS

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and composition

Gyrase inhibitors and uses thereof

The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordin

Gyrase inhibitors and uses thereof

The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates

Gyrase inhibitors and uses thereof

The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordi

A New Synthesis of α-Substituted δ-Carbolines

The paper describes a new general synthesis of α-substituted δ-carbolines based on key steps such as metalation, cross-coupling and cyclization.

Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles

New convergent synthesis of azacarbazoles through metalation, cross-coupling reaction and intramolecular substitution via (2-aminobenzene)boronic acid and ortho-fluoroiodopyridines.

First Metalation of Aryl Iodides: Directed Ortho-Lithiation of Iodopyridines, Halogen-Dance, and Application to Synthesis

Metalation of iodopyridines was succesfully achieved by LDA at low temperature.In many cases, lithiation is ortho directed by the iodo group which subsequently ortho-migrates very fast to give stabilized iodolithiopyridines.This procedure was applied to 2